Season 13 · Episode 14
S13 Ep14: Revumenib Shows Promise Across Menin-Sensitive AML Subtypes and Could Shift Treatment Paradigms: With Naval Daver, MD
OncLive® On Air · OncLive® On Air
June 12, 202511m 4s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In today’s episode, we spoke with Naval Daver, MD, about the evolving role of menin inhibition in acute myeloid leukemia (AML) and emerging data with revumenib (Revuforj) presented across ongoing clinical trials. Dr Daver is a professor in the Department of Leukemia and director of the Leukemia Research Alliance Program at The University of Texas MD Anderson Cancer Center in Houston, Texas.